![Bryant Lim](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bryant Lim
Directeur Financier/CFO chez
PRELUDE THERAPEUTICS INCORPORATED
Fortune : 107 408 $ au 31/05/2026
Profil
Bryant D.
Lim is currently Director at Life Sciences Pennsylvania since 2019.
Mr. Lim is also Secretary, Chief Financial & Accounting Officer at Prelude Therapeutics, Inc. starting in 2024.
Formerly, Mr. Lim was Chief Business Officer, SVP & General Counsel at Aceragen, Inc. from 2022 to 2023.
Prior to that, served as Secretary, Senior VP & General Counsel at Idera Pharmaceuticals, Inc. from 2018 to 2022.
From 2014 to 2018, held the position of Chief Compliance Officer & Vice President at Incyte Corp.
Also worked as Assistant Counsel at Merck & Co., Inc. and Associate General Counsel at Viropharma, Inc. Education includes undergraduate studies at Rochester Christian University and graduate studies at Villanova University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/04/2026 | 27 400 ( 0,04% ) | 107 408 $ | 31/05/2026 |
Postes actifs de Bryant Lim
| Sociétés | Poste | Début |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Directeur Financier/CFO | 08/04/2024 |
Life Sciences Pennsylvania
 Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Provides consulting services to biosciences industry | Directeur/Membre du Conseil | 01/05/2019 |
Anciens postes connus de Bryant Lim
| Sociétés | Poste | Fin |
|---|---|---|
| ACERAGEN, INC. | Conseiller Juridique Général | 17/02/2023 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Conseiller Juridique Général | 01/10/2022 |
| INCYTE CORPORATION | Compliance Officer | 01/09/2018 |
Viropharma, Inc. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Conseiller Juridique Général | - |
Formation de Bryant Lim
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Rochester Christian University
 Rochester Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Life Sciences Pennsylvania
Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Provides consulting services to biosciences industry | Commercial Services |
Villanova University School of Law
 Villanova University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Viropharma, Inc. | |
Aceragen, Inc.
 Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
